MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Machwate, M.
Right arrow Articles by Rodan, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Machwate, M.
Right arrow Articles by Rodan, G. A.

Vol. 60, Issue 1, 36-41, July 2001

Prostaglandin Receptor EP4 Mediates the Bone Anabolic Effects of PGE2

M. Machwate, S. Harada, C. T. Leu, G. Seedor, M. Labelle, M. Gallant, S. Hutchins, N. Lachance, N. Sawyer, D. Slipetz, K. M. Metters, S. B. Rodan, R. Young, and G. A. Rodan

Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, Pennsylvania (M.M., S.H., C.T.L., G.S., S.B.R., G.A.R.); and Merck Frosst, Kirkland, Quebec, Canada (M.L., M.G., S.H., N.L., N.S., D.S., K.M.M., R.Y.)

Prostaglandin (PG) E2 is a potent inducer of cortical and trabecular bone formation in humans and animals. Although the bone anabolic action of PGE2 is well documented, the cellular and molecular mechanisms that mediate this effect remain unclear. This study was undertaken to examine the effect of pharmacological inactivation of the prostanoid receptor EP4, one of the PGE2 receptors, on PGE2-induced bone formation in vivo. We first determined the ability of EP4A, an EP4-selective ligand, to act as an antagonist. PGE2 increases intracellular cAMP and suppresses apoptosis in the RP-1 periosteal cell line. Both effects were reversed by EP4A, suggesting that EP4A acts as an EP4 antagonist in the cells at concentrations consistent with its in vitro binding to EP4. We then examined the effect of EP4 on bone formation induced by PGE2 in young rats. Five- to 6-week-old rats were treated with PGE2 (6 mg/kg/day) in the presence or absence of EP4A (10 mg/kg/day) for 12 days. We found that treatment with EP4A suppresses the increase in trabecular bone volume induced by PGE2. This effect is accompanied by a suppression of bone formation indices: serum osteocalcin, extent of labeled surface, and extent of trabecular number, suggesting that the reduction in bone volume is due most likely to decreased bone formation. The pharmacological evidence presented here provides strong support for the hypothesis that the bone anabolic effect of PGE2 in rats is mediated by the EP4 receptor.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
S. Ramanadham, K. E. Yarasheski, M. J. Silva, M. Wohltmann, D. V. Novack, B. Christiansen, X. Tu, S. Zhang, X. Lei, and J. Turk
Age-Related Changes in Bone Morphology Are Accelerated in Group VIA Phospholipase A2 (iPLA2{beta})-Null Mice
Am. J. Pathol., April 1, 2008; 172(4): 868 - 881.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
G. Elberg, D. Elberg, T. V. Lewis, S. Guruswamy, L. Chen, C. J. Logan, M. D. Chan, and M. A. Turman
EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells
Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1622 - F1632.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
U. C. Kopp, M. Z. Cicha, L. A. Smith, J. Mulder, and T. Hokfelt
Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of {alpha}1- and {alpha}2-adrenoceptors on renal sensory nerve fibers
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1561 - R1572.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Nakao, A. Murase, H. Ohshiro, T. Okumura, K. Taniguchi, Y. Murata, M. Masuda, T. Kato, Y. Okumura, and J. Takada
CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4 Receptor Antagonist with Antihyperalgesic Properties
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 686 - 694.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. A. Bundey and P. A. Insel
Adenylyl Cyclase 6 Overexpression Decreases the Permeability of Endothelial Monolayers via Preferential Enhancement of Prostacyclin Receptor Function
Mol. Pharmacol., November 1, 2006; 70(5): 1700 - 1707.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
L. G. Raisz
Selective Prostaglandin Agonists as Anabolic Agents
IBMS BoneKEy, July 1, 2006; 3(7): 15 - 20.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
L. Aoudjit, A. Potapov, and T. Takano
Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor
Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1534 - F1542.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
S. C. Manolagas
Choreography from the Tomb: An Emerging Role of Dying Osteocytes in the Purposeful, and Perhaps Not So Purposeful, Targeting of Bone Remodeling
IBMS BoneKEy, January 1, 2006; 3(1): 5 - 14.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Mendez and M. C. LaPointe
PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2111 - H2117.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. L. Clarke, M. G. Belvisi, S. J. Smith, E. Hardaker, M. H. Yacoub, K. K. Meja, R. Newton, D. M. Slater, and M. A. Giembycz
Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor
Am J Physiol Lung Cell Mol Physiol, February 1, 2005; 288(2): L238 - L250.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. L. Clarke, M. G. Belvisi, E. Hardaker, R. Newton, and M. A. Giembycz
E-Ring 8-Isoprostanes Are Agonists at EP2- and EP4-Prostanoid Receptors on Human Airway Smooth Muscle Cells and Regulate the Release of Colony-Stimulating Factors by Activating cAMP-Dependent Protein Kinase
Mol. Pharmacol., February 1, 2005; 67(2): 383 - 393.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
U. C. Kopp, M. Z. Cicha, K. Nakamura, R. M. Nusing, L. A. Smith, and T. Hokfelt
Activation of EP4 receptors contributes to prostaglandin E2-mediated stimulation of renal sensory nerves
Am J Physiol Renal Physiol, December 1, 2004; 287(6): F1269 - F1282.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
C. H. Turner and A. G. Robling
Mechanical Loading and Bone Formation
IBMS BoneKEy, September 1, 2004; 1(9): 15 - 23.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Kuroda and U. Yamashita
Mechanisms of Enhanced Macrophage-Mediated Prostaglandin E2 Production and Its Suppressive Role in Th1 Activation in Th2-Dominant BALB/c Mice
J. Immunol., January 15, 2003; 170(2): 757 - 764.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Takayama, G. Garcia-Cardena, G. K. Sukhova, J. Comander, M. A. Gimbrone Jr., and P. Libby
Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor
J. Biol. Chem., November 8, 2002; 277(46): 44147 - 44154.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Yoshida, H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, T. Katayama, K. Yamaguchi, E. Segi, T. Tsuboyama, M. Matsushita, et al.
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation
PNAS, April 2, 2002; 99(7): 4580 - 4585.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Yoshida, H. Oida, T. Kobayashi, T. Maruyama, M. Tanaka, T. Katayama, K. Yamaguchi, E. Segi, T. Tsuboyama, M. Matsushita, et al.
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation
PNAS, April 2, 2002; 99(7): 4580 - 4585.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics